THE DEFINITIVE GUIDE TO AGO TUMOR

Molecular typing is based on molecular genetic testing and is not however routinely offered. Molecular subtypes and immunohistochemical surrogate markers from the tumors (HR, HER2, triple damaging) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 could be handy, but a possible